- 全部删除
您的购物车当前为空
Tolebrutinib (PRN2246) 是一种选择性、有效的、具有口服活性、可透过血脑屏障的布鲁顿氏酪氨酸激酶抑制剂,能够作用于 Ramos B 细胞 (IC50:0.4 nM)、HMC 小胶质细胞 (IC50:0.7 nM)。它对中枢神经系统免疫具有功效。它可用于多发性硬化症的研究。


为众多的药物研发团队赋能,
让新药发现更简单!
Tolebrutinib (PRN2246) 是一种选择性、有效的、具有口服活性、可透过血脑屏障的布鲁顿氏酪氨酸激酶抑制剂,能够作用于 Ramos B 细胞 (IC50:0.4 nM)、HMC 小胶质细胞 (IC50:0.7 nM)。它对中枢神经系统免疫具有功效。它可用于多发性硬化症的研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 247 | In stock | |
| 5 mg | ¥ 689 | In stock | |
| 10 mg | ¥ 1,160 | In stock | |
| 25 mg | ¥ 1,990 | In stock | |
| 50 mg | ¥ 2,960 | In stock | |
| 100 mg | ¥ 4,850 | In stock | |
| 200 mg | ¥ 6,730 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 690 | In stock |
Tolebrutinib 相关产品
| 产品描述 | Tolebrutinib (PRN2246) is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively). It exhibits efficacy in central nervous system immunity. Tolebrutinib can be used for the research of multiple sclerosis (MS). |
| 靶点活性 | BTK:0.4 nM (in Ramos B cells) , BTK:0.7 nM(in HMC microglia cell) |
| 体外活性 | PRN2246 inhibits microglial FcγR activation through durable occupancy of BTK, with an IC50 of 157 nM.?PRN2246 blocks the BCR-mediated activation (IC50=10 nM) and Fc receptor activation (IC50=166 and 9.6 nM for FcεR and FcγR, repectively) of immune cells[1]. |
| 体内活性 | PRN2246 produces dose-dependent protection from in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model[1] |
| 别名 | SAR442168, PRN2246 |
| 分子量 | 455.51 |
| 分子式 | C26H25N5O3 |
| CAS No. | 1971920-73-6 |
| Smiles | Nc1nccc2n([C@@H]3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12 |
| 密度 | 1.334 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (219.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容